Advanced

Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.

Braun, Oscar LU ; Bico, Besim LU ; Chaudhry, Uzma LU ; Wagner, Henrik LU ; Koul, Sasha LU ; Tydén, Patrik LU ; Scherstén, Fredrik LU ; Jovinge, Stefan LU ; Svensson, Peter LU and Smith, Gustav LU , et al. (2015) In Thrombosis Research 135(1). p.26-30
Abstract
Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin). However, there are uncertainties regarding the risk for thrombosis since poor-responsiveness to clopidogrel is common. Ticagrelor is a more potent platelet inhibitor, but data supporting concurrent use of ticagrelor and warfarin (dual antithrombotic therapy, DT) is limited. This study therefore sought to evaluate the risk of bleeding and thrombosis associated with DT after an acute coronary syndrome (ACS).
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Thrombosis Research
volume
135
issue
1
pages
26 - 30
external identifiers
  • pmid:25467434
  • wos:000346432600006
  • scopus:84922429372
ISSN
1879-2472
DOI
10.1016/j.thromres.2014.10.016
language
English
LU publication?
yes
id
d0a6a5b9-fe96-40a0-bd07-daeada782295 (old id 4912797)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25467434?dopt=Abstract
date added to LUP
2015-01-08 19:12:47
date last changed
2017-10-29 03:08:04
@article{d0a6a5b9-fe96-40a0-bd07-daeada782295,
  abstract     = {Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin). However, there are uncertainties regarding the risk for thrombosis since poor-responsiveness to clopidogrel is common. Ticagrelor is a more potent platelet inhibitor, but data supporting concurrent use of ticagrelor and warfarin (dual antithrombotic therapy, DT) is limited. This study therefore sought to evaluate the risk of bleeding and thrombosis associated with DT after an acute coronary syndrome (ACS).},
  author       = {Braun, Oscar and Bico, Besim and Chaudhry, Uzma and Wagner, Henrik and Koul, Sasha and Tydén, Patrik and Scherstén, Fredrik and Jovinge, Stefan and Svensson, Peter and Smith, Gustav and vanderPals, Jesper},
  issn         = {1879-2472},
  language     = {eng},
  number       = {1},
  pages        = {26--30},
  series       = {Thrombosis Research},
  title        = {Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.},
  url          = {http://dx.doi.org/10.1016/j.thromres.2014.10.016},
  volume       = {135},
  year         = {2015},
}